title: Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.
abstract: The active role of angiogenesis during disease progression is well recognized in solid tumors. In hematologic malignancies such as multiple myeloma (MM), it is not known whether tumor neovascularization is an epiphenomenon or whether it is actively involved in disease progression. At clinical presentation, myeloma disease and the associated angiogenesis are both well established. Here the 5T2MM murine model was used to analyze angiogenesis during preclinical myeloma stages. Bone marrow (BM) of 5T2MM-inoculated mice was analyzed at weekly intervals until the end stage of the disease. Histologic analysis and assessment of microvessel density (MVD) by CD31 staining demonstrated a preangiogenic stage of small tumor aggregates followed by an angiogenic switch and subsequently an angiogenic stage of progressive tumor growth and large, confluent tumor nodules. Flow cytometric analysis that indicated an increase in percentage CD45- MM cells preceded the angiogenic switch. Real-time polymerase chain reaction (RT-PCR) of sorted CD45+ and CD45- MM cells indicated higher vascular endothelial growth factor 120 (VEGF120) and VEGF164 transcripts in CD45- MM cells. VEGF enzyme-linked immunosorbent assay (ELISA) revealed high secretion by CD45- MM cells but no protein secretion by CD45+ MM cells, indicating angiogenic heterogeneity among the MM cells. These data suggest that, like in solid tumors, angiogenic switch and angiogenic heterogeneity exist in MM.
authors.affiliation: Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium. kewal.asosingh@vub.ac.be
authors.forename: Kewal
authors.initials: K
authors.lastname: Asosingh
authors.forename: Hendrik
authors.initials: H
authors.lastname: De Raeve
authors.forename: Eline
authors.initials: E
authors.lastname: Menu
authors.forename: Ivan
authors.initials: I
authors.lastname: Van Riet
authors.forename: Eric
authors.initials: E
authors.lastname: Van Marck
authors.forename: Benjamin
authors.initials: B
authors.lastname: Van Camp
authors.forename: Karin
authors.initials: K
authors.lastname: Vanderkerken
mesh_terms: D000818:Animals; D001483:Base Sequence; D018076:DNA, Complementary / Q000235:genetics; D015870:Gene Expression; D017493:Leukocyte Common Antigens / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009101:Multiple Myeloma / Q000098:blood supply* / Q000235:genetics / Q000276:immunology*; D009389:Neovascularization, Pathologic; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D018076:DNA, Complementary; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; D017493:Leukocyte Common Antigens